ImmunoGen, Inc. Announces Webcast of Presentation at the 2010 Barclays Capital Global Healthcare Conference
March 18 2010 - 10:15AM
Business Wire
ImmunoGen, Inc. (Nasdaq:
IMGN) is scheduled to present at the 2010 Barclays Capital Global
Healthcare Conference at 3:45 pm ET on March 24,
2010. The Conference is being held at the Loews Miami Beach Hotel
in Miami Beach, Florida. ImmunoGen’s presentation will be webcast
live and can be accessed through the “Investor Information” section
of our website, www.immunogen.com. An archive of the webcast will
be available at the same location until April 1, 2010.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cell-killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s cancer-cell killing agents
specifically to tumor targets. In addition to the Company’s product
pipeline, compounds utilizing the TAP technology are in clinical
testing through ImmunoGen’s collaborations with Genentech (a wholly
owned member of the Roche Group), sanofi-aventis, Biogen Idec and
Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in
Phase III testing being conducted by Genentech and Roche.
Other ImmunoGen collaborative partners include Bayer HealthCare and
Amgen. More information about ImmunoGen can be found at
www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024